Skip to main content
Arielle Medford, MD, Oncology, Boston, MA

ArielleJanineMedfordMD

Oncology Boston, MA

Resident

Dr. Medford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Medford's full profile

Already have an account?

  • Office

    55 Fruit St
    Boston, MA 02114
    Phone+1 617-643-0596
    Fax+1 617-643-6443

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2017 - 2019
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2015

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2016 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Identifying Opportunities to De-Escalate Adjuvant Therapy in Localized HER2+ Breast Cancer
    Identifying Opportunities to De-Escalate Adjuvant Therapy in Localized HER2+ Breast CancerMay 23rd, 2023
  • Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022
    Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022November 26th, 2022
  • CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)
    CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)April 2nd, 2024